trandolapril的影响及其与维拉帕米的固定剂量组合循环粘附分子水平与2型糖尿病的高血压患者。

文章的细节

引用

复制到剪贴板

Rubio-Guerra房颤,Vargas-Robles H, Vargas-Ayala G, Rodriguez-Lopez L, Escalante-Acosta英航

trandolapril的影响及其与维拉帕米的固定剂量组合循环粘附分子水平与2型糖尿病的高血压患者。

Exp Hypertens。2008年10月,30 (7):682 - 8。doi: 10.1080 / 10641960802251941。

PubMed ID

18855271 (在PubMed

]

文摘

背景和目的:在高血压内皮功能障碍2型糖尿病患者与水平的提高循环可溶性粘附分子(SAM)。山姆参与糖尿病大血管病变和微血管病变上的发展。本研究的目的是比较的影响trandolapril (T)和它的固定剂量组合与维拉帕米(FDTV)山姆水平高血压2型糖尿病患者。方法:40 2型糖尿病患者对高血压患者被随机分配到两组。一组(FDTV)收到2/180毫克每天一次;另一组接受T 2毫克每天一次。研究药物管理三个月两组。VCAM-1、ICAM E-selectin ELISA测定的研究的开始和结束。患者评估每月对血压、空腹血清葡萄糖和不良事件。与方差分析进行统计分析。 RESULTS: Both therapeutics regimens reduced significantly the levels of the SAM tested. When both groups were compared, we did not find a significant difference in ICAM and E-selectin reduction. However, VCAM-1 presented a significantly greater reduction (p = 0.022) in the trandolapril-verapamil group. No patient suffered adverse events. CONCLUSION: Our results show that FDTV produces a greater reduction of VCAM-1 circulating levels than trandolapril alone. This may explain some of the beneficial effects of this fixed dosed combination that are non-related to its antihypertensive effects.

beplay体育安全吗DrugBank数据引用了这篇文章

药物

Trandolapril